Feasibility study of rapid opioid rotation and titration.
BACKGROUND
Opioid guidelines recommend opioid rotation and switching for patients who do not achieve adequate pain relief or who experience intolerable adverse events (AEs) with their current opioid. However, specific recommendations and protocols for opioid rotation are lacking, making the practice time consuming and difficult for primary care physicians to accomplish independently or coordinate with a pain specialist.


OBJECTIVE
To assess the safety and feasibility of using 24-hour intravenous patient-controlled analgesia (IV-PCA) to achieve rapid opioid rotation and titration (RORT).


METHODS
Open-label pilot study.


METHODS
Hospital research center.


METHODS
At admission, patients (aged ≥ 18 years) with treatment-refractory chronic pain who were taking morphine or oxycodone for ≥ 3 months and had pain scores ≥ 4 on a 10-point scale, underwent opioid rotation to oral oxymorphone extended release (ER). They also received IV-PCA oxymorphone for 24 hours as needed. At discharge, the participants were taking oral oxymorphone ER with oxymorphone immediate release (IR) as needed based on their total 24-hour oral plus IV-PCA oxymorphone use. During a 2-week follow-up, their oxymorphone usage was titrated as needed. Main outcome measures were AEs, Patient Global Impression of Change (PGIC), Brief Pain Inventory (0 = no pain/interference, 10 = worst pain/complete interference), treatment satisfaction, and change in oxymorphone dose.


RESULTS
Twelve patients enrolled and completed the 24-hour IV-PCA; 10 completed the 2-week follow-up post-24-hour IV-PCA. PGIC status improved by 12 hours (odds ratio [OR], 0.19, 95% CI, 0.08 - 0.44; P < 0.001), and both PGIC status and activity scores improved by 24 hours (OR, 0.23, 95% CI, 0.09 - 0.55; P = 0.001; OR, 0.49, 95% CI, 0.25 - 0.96; P = 0.04, respectively) and 2 weeks (OR, 0.14, 95% CI, 0.04 - 0.46; P = 0.001; OR, 0.21, 95% CI, 0.06 - 0.72; P = 0.01) versus 6 hours. During the 24-hour IV-PCA time period, 6 of 10 patients accomplished ≥ 50% of their overall dose titration. At 2 weeks, 8 of 10 participants were Greatly Satisfied or Somewhat Satisfied with the overall RORT procedure. RORT was well tolerated, with no serious AEs.


CONCLUSIONS
This was a pilot open-label study in a small number of participants. A larger randomized study with long-term follow-up and comparison to traditional protocols is necessary.


CONCLUSIONS
Preliminary data suggest that RORT can be performed safely and effectively by incorporating IV-PCA during the first 24 hours. Further investigations are needed to determine whether RORT can become an ambulatory treatment intervention in pain practice.
Mount Sinai Hospital and School of Medicine, Department of Anesthesiology, New York, NY 10029, USA.
Marina
M
Korkmazsky
Javid
J
Ghandehari
Angela
A
Sanchez
Hung-Mo
HM
Lin
Huong-Mo
HM
Lin
Marco
M
Pappagallo
D000284:Administration, Oral; D000328:Adult; D000698:Analgesia / Q000009:adverse effects / Q000379:methods*; D000701:Analgesics, Opioid / Q000008:administration & dosage* / Q000009:adverse effects; D002908:Chronic Disease; D004334:Drug Administration Schedule; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous / Q000009:adverse effects / Q000379:methods; D008297:Male; D008875:Middle Aged; D009020:Morphine / Q000008:administration & dosage / Q000009:adverse effects; D017063:Outcome Assessment, Health Care / Q000379:methods; D010098:Oxycodone / Q000008:administration & dosage / Q000009:adverse effects; D010111:Oxymorphone / Q000008:administration & dosage / Q000009:adverse effects; D010148:Intractable Pain / Q000188:drug therapy*; D010865:Pilot Projects; D012646:Self Administration / Q000009:adverse effects / Q000379:methods
D000701:Analgesics, Opioid; D009020:Morphine; D010111:Oxymorphone; D010098:Oxycodone
Curr Med Res Opin. 2009 Sep;25(9):2133-50
19601703
Minerva Anestesiol. 2005 Jul-Aug;71(7-8):425-33
16012415
J Pain. 2009 Feb;10(2):147-59
19187891
Pain. 1992 Apr;49(1):87-91
1375728
J Pain. 2010 Sep;11(9):807-29
20430701
J Clin Oncol. 2005 Aug 1;23(22):5229-34
16051965
Joint Bone Spine. 2002 Oct;69(5):491-4
12477234
Pain. 2001 Nov;94(2):149-158
11690728
Clin Ther. 2009 Feb;31(2):347-59
19302907
J Pain. 2003 Jun;4(5):231-56
14622694
Cancer. 2002 Jul 1;95(1):203-8
12115334
Osteoarthritis Cartilage. 2008 Feb;16(2):137-62
18279766
Pain Med. 2008 May-Jun;9(4):444-59
18489635
South Med J. 2010 Aug;103(8):738-47
20622716
Pain Pract. 2010 Mar-Apr;10(2):85-93
20070552
Pain. 2005 Jan;113(1-2):9-19
15621359
Hepatology. 2005 Dec;42(6):1364-72
16317692
Pain Physician. 2010 Sep-Oct;13(5):401-35
20859312
J Pain Symptom Manage. 2009 Sep;38(3):418-25
19735902
Pain Physician. 2008 Mar;11(2 Suppl):S105-20
18443635
J Pain. 2007 Feb;8(2):175-84
17145204
J Opioid Manag. 2008 Jul-Aug;4(4):201-11
18837203
Pain Physician. 2008 Mar;11(2 Suppl):S5-S62
18443640
J Pain. 2009 Feb;10(2):113-30
19187889
Anesth Analg. 2000 Apr;90(4):933-7
10735802
Am J Hosp Palliat Care. 2008 Dec-2009 Jan;25(6):431-9
18812615
Pain Med. 2008 May-Jun;9(4):433-43
18489634
Pain Physician. 2006 Jul;9(3):215-25
16886030